Tomáš Cihlář

Tomáš Cihlář (born 1967) is a prominent Czech biochemist renowned for his significant contributions to the field of virology, particularly in the development of remdesivir, an antiviral drug used in the treatment of COVID-19. Cihlář holds the positions of Senior Director, Biology, and Vice-President at Gilead Sciences, an American pharmaceutical company known for its advancements in antiviral medications.

Early Life and Education

Tomáš Cihlář was born in 1967 in the Czech Republic. From an early age, he showed a keen interest in the sciences, which led him to pursue a career in biochemistry. Cihlář completed his undergraduate and graduate studies at a prestigious university in the Czech Republic, where he focused on biochemistry and virology, laying the groundwork for his future research endeavors.

Career

Cihlář's career is marked by his collaboration with renowned biochemist Antonín Holý, a partnership that significantly impacted the field of antiviral research. As a student, Cihlář assisted Holý in the development of Viread (Tenofovir disoproxil), a groundbreaking drug that has become a cornerstone in the treatment of HIV/AIDS.

Following his work on Viread, Cihlář joined Gilead Sciences, where he has been instrumental in the development of several antiviral therapies. His most notable achievement at Gilead is his role in the development of remdesivir, an antiviral drug that has been authorized for emergency use in the treatment of COVID-19 in many countries around the world. Remdesivir works by inhibiting the replication of the SARS-CoV-2 virus, which causes COVID-19, thereby helping to mitigate the severity of the disease in hospitalized patients.

Contributions to Virology

Cihlář's contributions to virology extend beyond the development of specific drugs. He has been involved in extensive research aimed at understanding the mechanisms of viral replication and the body's response to viral infections. His work has paved the way for the development of novel therapeutic strategies against a variety of viral pathogens.

Awards and Recognition

Throughout his career, Tomáš Cihlář has received numerous awards and recognitions for his contributions to biochemistry and virology. His work on antiviral drugs, especially in the context of the COVID-19 pandemic, has garnered international acclaim, highlighting the global impact of his research.

See Also

• Antiviral drug
• Gilead Sciences
• COVID-19 pandemic
• HIV/AIDS

External Links

• [Gilead Sciences Official Website]